News & Resources
| [Dec18] Daewoong Pharmaceutical to create world’s first oral novel drug for severe liver fibrosis | |||
| Name | KPBMA | ||
|---|---|---|---|
| Registration date | 2024/12/20 | ||
| Links(files, etc.) | |||
|
Daewoong Pharmaceutical is developing the first oral treatment for ‘severe liver fibrosis’. The company announced on December 18 that its novel drug candidate, ‘DWP220 (development code name),’ was selected for the ‘2024 2nd National New Drug Development Project’ hosted by the Korea Drug Development Fund (KDDF). |
|||
| Prev | [Dec13] Boryung partners with Taiwan Lotus for cytotoxic anticancer drug CDMO agreement, targeting supply in 2026 | ||
| Next | [Dec19] Celltrion’s autoimmune disease treatment ‘Steqeyma’ approved by U.S. FDA, set for launch in February 2025 | ||